GLPG-3067/GLPG-2222/GLPG-2737

N/A

Report date: 2025/07/31 17:26:18

Base Information

Drug NameGLPG-3067/GLPG-2222/GLPG-2737

Drug Alias NameGLPG-3067 + GLPG-2222 + GLPG-2737ABBV-3067 + ABBV-2222 + ABBV-2737GLPG-2222/GLPG-3067/GLPG-2737GLPG-2737/GLPG-3067/GLPG-2222GLPG-3067/GLPG-2737/GLPG-2222

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators

TargetsCystic fibrosis transmembrane conductance regulator

Therapy Area/IndicationsCystic Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Navocaftor Galicaftor ABBV-2737

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGalapagos Nv Abbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc Galapagos Nv

Inactive CompaniesN/A

Active IndicationsCystic Fibrosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A